A recent Phase 3 study has revealed the advantages of the initial flu vaccine that incorporates three established methods to boost immunity for seniors into one vaccine. The study was conducted in Maidenhead, United Kingdom, with results released on September 10, 2026. CSL Seqirus, a subsidiary of CSL (listed on ASX: CSL and USOTC: CSLLY), conducted the study.